Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Works matching IS 11732563 AND DT 2019 AND VI 39 AND IP 5
Results: 10
1
2
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 477, doi. 10.1007/s40261-019-00775-8
- By:
- Publication type:
- Article
3
Chronic Use of β-Blockers and the Risk of Parkinson's Disease.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 463, doi. 10.1007/s40261-019-00771-y
- By:
- Publication type:
- Article
4
Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 469, doi. 10.1007/s40261-019-00770-z
- By:
- Publication type:
- Article
5
The Combination of Lithium and ACE Inhibitors: Hazardous, Critical, Possible?
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 485, doi. 10.1007/s40261-019-00768-7
- By:
- Publication type:
- Article
6
Prescribing Trends of Codeine-containing Medications and Other Opioids in Primary Care After A Regulatory Decision: An Interrupted Time Series Analysis.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 455, doi. 10.1007/s40261-019-00767-8
- By:
- Publication type:
- Article
7
Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report of an Adolescent Girl.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 491, doi. 10.1007/s40261-019-00766-9
- By:
- Publication type:
- Article
8
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 441, doi. 10.1007/s40261-019-00764-x
- By:
- Publication type:
- Article
9
Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 429, doi. 10.1007/s40261-019-00762-z
- By:
- Publication type:
- Article
10
Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 5, p. 421, doi. 10.1007/s40261-019-00765-w
- By:
- Publication type:
- Article